TransMedics Group (NASDAQ:TMDX) Stock Price Down 4.4% - Here's Why

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s stock price fell 4.4% on Wednesday . The stock traded as low as $62.80 and last traded at $62.80. 598,790 shares were traded during trading, a decline of 43% from the average session volume of 1,047,481 shares. The stock had previously closed at $65.71.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research reports. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 11th. Oppenheimer reiterated an "outperform" rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. TD Cowen decreased their target price on shares of TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. Finally, Piper Sandler lowered their target price on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Price Performance

The firm has a market capitalization of $2.04 billion, a P/E ratio of 64.77 and a beta of 2.06. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business's 50 day moving average is $91.40 and its 200-day moving average is $129.80.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the business posted ($0.12) EPS. The company's revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company's stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the business's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 19,417 shares of company stock valued at $2,240,738. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. State of Alaska Department of Revenue acquired a new position in TransMedics Group in the 3rd quarter worth about $2,560,000. Charles Schwab Investment Management Inc. grew its holdings in shares of TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company's stock worth $42,656,000 after purchasing an additional 6,634 shares during the last quarter. Zacks Investment Management acquired a new position in shares of TransMedics Group in the third quarter valued at approximately $1,607,000. Vaughan Nelson Investment Management L.P. raised its holdings in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company's stock valued at $51,654,000 after buying an additional 64,360 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company's stock valued at $11,716,000 after buying an additional 64,872 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.